スポンサーサイト

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。


Cancer Topics Index 04/04/2016(Daily Test version/ 日刊テスト版)No.02

konpas.jpg
Cancer Topics Index 04/02/2016(Daily Test version/ 日刊テスト版)

Flags 【海外:overseas】
Clinicaltrials.gov:臨床試験>
※2週間前の情報を基準として掲載いたします。
19 studies found for: cancer | received from 03/20/2016 to 03/21/2016

【肺がん】
1 Recruiting
Additive Value of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy
Condition: Lung Cancer
Intervention: Procedure: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
Sponsor:M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:NCT02719847

【乳がん】
2 Not yet recruiting
The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Conditions: Breast Neoplasms; Triple Negative Breast Neoplasms
Interventions: Drug: Dasatinib; Procedure: Conventional Surgery; Other: Laboratory Biomarker Analysis
Sponsor:University of Wisconsin, Madison
ClinicalTrials.gov Identifier:NCT02720185

【乳がん】
3 Not yet recruiting
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Conditions: Metastatic Breast Cancer; Solid Tumors
Interventions: Drug: Alisertib; Drug: MLN0128
Sponsor:University of Colorado, Denver
ClinicalTrials.gov Identifier:NCT02719691

【乳がん】
4 Not yet recruiting
Breast Cancer Lung Late Effects
Conditions: Radiation Injury; Breast Cancer
Interventions: Radiation: Proton beam radiation therapy.; Radiation: X-ray based radiation therapy; Procedure: Computed Tomography (CT) Scan; Procedure: Pulmonary Function Test (PFT)
Sponsor:University of Florida
ClinicalTrials.gov Identifier:NCT02725840

【がんサバイバー】
5 Active, not recruiting
Web-based Study for Cancer Survivors
Conditions: Physical Activity; Dietary Modification
Intervention: Behavioral: ALIVE
Sponsor:University of North Texas Health Science Center
ClinicalTrials.gov Identifier:NCT02722850

【がん】
6 Not yet recruiting
A Phase I/II Study of CX5461
Condition: Cancer
Intervention: Drug: CX5461
Sponsor:Canadian Cancer Trials Group
ClinicalTrials.gov Identifier:NCT02719977

【リンパ嚢腫】
7 Recruiting
Symptomatic Ascites and Lymphocysts Drainage With a Patient-controlled Vascular Catheter.
Conditions: Malignant Ascites; Lymphocele
Interventions: Device: Ascites drainage with vascular catheter.; Device: Lymphocele drainage with vascular catheter, sclerotherapy.; Device: Interview.; Device: Quality of life.; Device: Quality of procedure.; Device: Risk of malnutrition.; Device: Sclerotherapy.
Sponsor:Maciej Stukan, MD, PhD
ClinicalTrials.gov Identifier:NCT02724683

【婦人科悪性腫瘍】
8 Not yet recruiting
The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures
Condition: Gynecological Malignancies
Intervention: Device: Mid-Infrared Spectroscopy with ATR
Sponsor:Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:NCT02718209

【固形がん】
11 Not yet recruiting
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: LY3022855; Drug: Durvalumab; Drug: Tremelimumab
Sponsor:Eli Lilly and Company
ClinicalTrials.gov Identifier:NCT02718911

【黒色腫】
12 Not yet recruiting
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: rAd.CD40L; Drug: Pembrolizumab
Sponsor:M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:NCT02719015

【GPC3陽性肝細胞がん】
13 Recruiting
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Conditions: GPC3 Positive Hepatocellular Carcinoma; CAR-T Cell Immunotherapy
Intervention: Biological: CAR-T cell immunotherapy
Sponsor:Fuda Cancer Hospital, Guangzhou
ClinicalTrials.gov Identifier:NCT02723942

【局所進行肝門部胆管がん】
15 Recruiting
Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma
Conditions: Treatment Response; Adverse Events; Feasibility
Intervention: Procedure: Photodynamic therapy
Sponsor:Asan Medical Center
ClinicalTrials.gov Identifier:NCT02725073

【再発肝細胞がん】
16 Recruiting
TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation
Condition: Recurrent Hepatocellular Carcinoma
Intervention: Other: Biological: HBV antigen specific TCR redirected T cell
Sponsor:Lion TCR Pte. Ltd.
ClinicalTrials.gov Identifier:NCT02719782

【骨髄線維症】
18 Not yet recruiting
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INCB050465; Drug: Ruxolitinib
Sponsor:Incyte Corporation
ClinicalTrials.gov Identifier:NCT02718300

【急性骨髄性白血病】
19 Not yet recruiting
Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation
Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome
Interventions: Drug: FT-2102; Drug: Azacitidine
Sponsor:Forma Therapeutics, Inc.
ClinicalTrials.gov Identifier:NCT02719574

<Medical Journal & Other News>
【放射性ヨウ素治療が生殖能力に影響を与える可能性】
Radioactive iodine treatment in women affects ovarian reserve and may affect fertility (2 APR 2016 EurekAlert!)
THE ENDOCRINE SOCIETY

【神経内分泌前立腺がんのがん遺伝子を特定】
UCLA scientists pinpoint cancer gene responsible for neuroendocrine prostate cancer (March 31, 2016 UCLA Newsroom)

【多発性骨髄腫】
Aplidin shows positive results in pivotal Phase 3 clinical trial for multiple myeloma (31 MAR 2016 EurekAlert!)
PharmaMar intends to submit a Marketing Authorization Application to the European Medicines Agency during the last quarter of this year
PHARMAMAR
Aplidinが多発性骨髄腫のピボタル第III相臨床試験で肯定的な結果示す (04/01/2016 共同通信PRワイヤー:日本語)

【長期のベジタリアンダイエットに、がん・心臓病のリスク】
Long-Term Vegetarian Diet Increases Risk of Heart Disease and Cancer (30 Mar 2016 Newsmax)

Graphics 【日本国内:Japan】
<Press Release:日本国内>
【結腸・直腸がん】
TAS-102(「ロンサーフ®配合錠T15・T20」) 進行・再発の結腸・直腸がん患者を対象とするアジア臨床第Ⅲ相試験で全生存期間を有意に延長 -アジア諸国での早期申請を目指す- (04/01/2016 大鵬薬品工業 Taiho Pharmaceutical)
TAS-102「ロンサーフ」は、トリフルリジン(FTD)とチピラシル塩酸塩(TPI)を配合した経口のヌクレオシド系抗悪性腫瘍剤で、フルオロピリミジンとは異なる作用機序を有しています。FTDはDNAの複製時にチミジンの代わりにDNA鎖に取り込まれ、DNAの機能障害を引き起こして抗腫瘍効果を発揮すると推測されています。TPI はFTDの分解に関与するチミジンホスホリラーゼ(TP)を阻害し、FTDの血中濃度を維持します。

<News>
がんの名医が選ぶ「私が診てもらいたいがんの名医」50人 (04/03/2016 現代ビジネス賢者の知恵)

「学会は消滅?」「医局復権に利用された」◆Vol.1 医師会員2000人に調査、新専門医制度の問題点 (04/02/2016 m3.com)

抗がん剤[分子標的薬]が効くかどうか20分で分かる検査キットを名大が開発!3年後実用化へ、将来はがんの早期診断への応用も (04/02/2016 Newswitch)
0403.jpg

ATL[成人T細胞白血病] 新薬[DS-3201b]治験始まる 高確率でがん細胞根絶 3年後の薬事承認目指す (04/01/2016 西日本新聞)

胸膜中皮腫の新治療法として注目される「NK4遺伝子」(04/01/2016 NEWSポストセブン)
<記事を追跡:Follow-up story>
NK4遺伝子を用いた悪性中皮腫の臨床研究 (千葉大学医学部附属病院)
切除不能悪性胸膜中皮腫を対象としたNK4遺伝子発現型アデノウィルスベクターによる臨床研究 (千葉大学附属病院呼吸器内科)

<新刊メタデータ:New Books>
【タイトル】がん患者よ、近藤誠を疑え
著者:近藤 誠/単行本(ソフトカバー): 312ページ/出版社: 日本文芸社 (2016/3/30)/ISBN-10: 4537261382/ISBN-13: 978-4537261387/¥1,512
関連記事


コメント
コメントの投稿


管理者にだけ表示を許可する

トラックバック
http://paxxmedia.blog38.fc2.com/tb.php/8984-88a6a520
この記事にトラックバックする(FC2ブログユーザー)


上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。